{"id":388410,"date":"2020-11-25T08:03:20","date_gmt":"2020-11-25T13:03:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388410"},"modified":"2020-11-25T08:03:20","modified_gmt":"2020-11-25T13:03:20","slug":"vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/","title":{"rendered":"VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference"},"content":{"rendered":"
\n

BRIDGEWATER, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d) today announced that David Domzalski, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020.<\/p>\n

A recording of the fireside chat will be accessible to institutional clients of Piper Sandler beginning December 1, 2020 via Piper Sandler\u2019s event portal.\u00a0The Company will be available for institutional investor meetings on December 1, 2020.<\/p>\n

\n About VYNE Therapeutics Inc.<\/strong>
\n
In March 2020, Menlo Therapeutics Inc. (“Menlo”) and Foamix Pharmaceuticals Ltd. (\u201cFoamix\u201d) combined to form what is now known as VYNE Therapeutics Inc. VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.<\/p>\n

With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST\u2122), and has received FDA approval for AMZEEQ\u00ae (minocycline) topical foam, 4%, the world\u2019s first topical minocycline, and for ZILXI\u2122 (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ\u2019s Full Prescribing Information at AMZEEQ.com<\/a> and ZILXI\u2019s Full Prescribing Information at ZILXI.com<\/a>.<\/p>\n

For more information about VYNE Therapeutics Inc. or its investigational products, visit http:\/\/www.vynetherapeutics.com\/<\/a> or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE\u2019s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.<\/p>\n

\n CONTACT:<\/strong>
\n
Joyce Allaire
LifeSci Advisors, LLC
646-889-1200
jallaire@lifesciadvisors.com<\/p>\n

Andrew Saik
Chief Financial Officer
VYNE Therapeutics
908-731-6180
Andrew.Saik@vynetx.com<\/p>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BRIDGEWATER, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d) today announced that David Domzalski, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020. A recording of the fireside chat will be accessible to institutional clients of Piper Sandler beginning December 1, 2020 via Piper Sandler\u2019s event portal.\u00a0The Company will be available for institutional investor meetings on December 1, 2020. About VYNE Therapeutics Inc. In March 2020, Menlo Therapeutics Inc. (“Menlo”) and Foamix Pharmaceuticals Ltd. (\u201cFoamix\u201d) combined to form what is now known as VYNE Therapeutics Inc. VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and … <\/p>\n

Continue reading “VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388410","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRIDGEWATER, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d) today announced that David Domzalski, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020. A recording of the fireside chat will be accessible to institutional clients of Piper Sandler beginning December 1, 2020 via Piper Sandler\u2019s event portal.\u00a0The Company will be available for institutional investor meetings on December 1, 2020. About VYNE Therapeutics Inc. In March 2020, Menlo Therapeutics Inc. (“Menlo”) and Foamix Pharmaceuticals Ltd. (\u201cFoamix\u201d) combined to form what is now known as VYNE Therapeutics Inc. VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and … Continue reading "VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-25T13:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTkxMCMzODQzMDgyIzIwOTM4MDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference\",\"datePublished\":\"2020-11-25T13:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\\\/\"},\"wordCount\":309,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTkxMCMzODQzMDgyIzIwOTM4MDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\\\/\",\"name\":\"VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTkxMCMzODQzMDgyIzIwOTM4MDM=\",\"datePublished\":\"2020-11-25T13:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTkxMCMzODQzMDgyIzIwOTM4MDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTkxMCMzODQzMDgyIzIwOTM4MDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk","og_description":"BRIDGEWATER, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (\u201cVYNE\u201d or the \u201cCompany\u201d) today announced that David Domzalski, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference being held December 1-3, 2020. A recording of the fireside chat will be accessible to institutional clients of Piper Sandler beginning December 1, 2020 via Piper Sandler\u2019s event portal.\u00a0The Company will be available for institutional investor meetings on December 1, 2020. About VYNE Therapeutics Inc. In March 2020, Menlo Therapeutics Inc. (“Menlo”) and Foamix Pharmaceuticals Ltd. (\u201cFoamix\u201d) combined to form what is now known as VYNE Therapeutics Inc. VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and … Continue reading \"VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-25T13:03:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTkxMCMzODQzMDgyIzIwOTM4MDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference","datePublished":"2020-11-25T13:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/"},"wordCount":309,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTkxMCMzODQzMDgyIzIwOTM4MDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/","name":"VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTkxMCMzODQzMDgyIzIwOTM4MDM=","datePublished":"2020-11-25T13:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTkxMCMzODQzMDgyIzIwOTM4MDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTkxMCMzODQzMDgyIzIwOTM4MDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vyne-therapeutics-to-present-at-the-32nd-annual-piper-sandler-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388410"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388410\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}